The application of EPSiT in pilonidal sinus disease: an international Delphi consensus study endorsed by the Association of Laparoscopic Surgeons of Great Britain and Ireland (ALSGBI) - Summary - MDSpire

The application of EPSiT in pilonidal sinus disease: an international Delphi consensus study endorsed by the Association of Laparoscopic Surgeons of Great Britain and Ireland (ALSGBI)

  • By

  • H. K. Sekhon Inderjit Singh

  • P. Meinero

  • F. C. Campanile

  • A. Quddus

  • R. Rajaganeshan

  • J. Warusavitarne

  • V. Dotlacil

  • A. Bhargava

  • P. Giordano

  • A. Pini Prato

  • V. Shatkar

  • P. Jalali

  • V. C. Halahakoon

  • G. Gallo

  • M. Milone

  • S. Mantoo

  • C. A. Leo

  • C. Esposito

  • M. Farghaly

  • T. Arulampalam

  • N. Pawa

  • July 30, 2025

  • 0 min

Share

Objective:

To develop recommendations and a protocol to standardize and improve the uptake of endoscopic pilonidal sinus treatment (EPSiT) for pilonidal sinus disease (PD), focusing on addressing existing barriers.

Key Findings:
  • EPSiT and VAAPS are minimally invasive techniques with reduced complications compared to traditional surgeries.
  • Despite benefits, EPSiT uptake in the UK is low, with only 7% of cases from 2019 to 2022 utilizing this method, highlighting significant barriers to adoption.
  • Concerns regarding the technique's effectiveness in primary and recurrent disease contribute to slow adoption.
Interpretation:

The study highlights the need for standardized protocols to enhance the adoption of EPSiT, addressing existing ambiguities, training gaps, and barriers to implementation.

Limitations:
  • The study's findings are based on expert opinions and may not reflect broader surgical practice, potentially limiting generalizability.
  • Potential biases in participant selection and response may affect the consensus outcomes, impacting the reliability of the recommendations.
Conclusion:

The Delphi consensus aims to facilitate the integration of EPSiT into clinical practice, promoting its use as a preferred treatment for pilonidal sinus disease by addressing identified barriers.

Original Source(s)

Related Content